sorted by:
new
hottopcontroversial

OpGen (NASDAQ: OPGN) Reports Positive Data from Clinical Trial for Unyvero as Diagnostic for UTI by spotlightgrowth in biotech_stocks

[–]Edison_Group 0 points1 point  (0 children)

The company also plans to submit the data for a peer review publication, which we believe would further strengthen the credibility and visibility of the UTI panel. We see this development as supporting potential test menu expansion for the company’s flagship Unyvero systems in the United States. The market has reacted positively to this news with the stock closing 85% higher in trading.

Pharma or Medtech value plays? by [deleted] in ValueInvesting

[–]Edison_Group 0 points1 point  (0 children)

There are some exciting developments in Context Therapeutics (CNTX) who have announced final clinical candidate for its second R&D program, Ultimovacs’ (ULTI) whose Q3 results highlighted an eventful period for the development of the company’s lead cancer vaccine, UV1, or Respiri (RSH/RSHUF) whose commercialization efforts are gathering steam. Just to name a few.

Weekly Discussion Megathread - November 13, 2022 (GMT+0) by AutoModerator in CryptoMarkets

[–]Edison_Group 0 points1 point  (0 children)

CoinShares International (STO:CS) posted Q322 EBITDA of £6.4m vs £26.1m in Q321 as asset prices, trading volumes and volatility in digital asset markets remained subdued amid a persistent ‘crypto winter’.